Hepatitis C-Therapieansprechbarkeit

Thompson AJ et al. (2010) Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Jopling CL et al. (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.

Dawes R et al. (2006) Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection.

Evans MJ et al. (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.

Zheng A et al. (2007) Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus.

Ge D et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Li Q et al. (2009) A genome-wide genetic screen for host factors required for hepatitis C virus propagation.

Tanaka Y et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Suppiah V et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Thomas DL et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Lanford RE et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.

Fellay J et al. (2010) ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

Bowen DG et al. (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection.

Herker E et al. (2010) Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1.

Lupberger J et al. (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Sainz B et al. (2012) Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.

Prokunina-Olsson L et al. (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Bibert S et al. (2013) IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction.

Maehama T et al. (2013) A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication.

Okamoto M et al. (2014) IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection.

Duong FH et al. (2014) IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies.

Lin RJ et al. (2014) MCPIP1 suppresses hepatitis C virus replication and negatively regulates virus-induced proinflammatory cytokine responses.

Majzoub K et al. (2014) RACK1 controls IRES-mediated translation of viruses.

Kim N et al. (2016) Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A.

Tseng CT et al. (2002) Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions.

Huang Y et al. (2007) A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection.

Foy E et al. (2003) Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease.

Agnello V et al. (1999) Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Price DA et al. (2006) Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection.

Pileri P et al. (1998) Binding of hepatitis C virus to CD81.

Tan SL et al. (1999) NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling.

Taylor DR et al. (1999) Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.

Thursz M et al. () Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research.

Jin DY et al. (2000) Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation.

Kruger M et al. (2000) Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach.

Crotta S et al. (2002) Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.

Khakoo SI et al. (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection.

He Y et al. (2002) Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase.

Scarselli E et al. (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Bosserhoff AK et al. (2003) Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes.

Pöhlmann S et al. (2003) Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR.

Gardner JP et al. (2003) L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus.

None (2004) Pathophysiology of hepatitis C virus infection and related liver disease.

Goulding C et al. (2005) The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source.

Wang C et al. (2005) Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication.

None (2005) Unscrambling hepatitis C virus-host interactions.

Lindenbach BD et al. (2005) Unravelling hepatitis C virus replication from genome to function.

Gale M et al. (2005) Evasion of intracellular host defence by hepatitis C virus.